Development of an Age‐Dependent Antibiogram in a Veterans Affairs Community

Ventura, MaryAnne M.; Brittain, Kevin; Pruskowski, Jennifer; D, Hogan; Walker, Tiffany

doi:10.1111/jgs.13224

Cited by 1 publication

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antimicrobial prescription and institutional antibiograms differ between various institutions, sometimes even within an individual health-care institution 60,62,63 , and between inpatient and outpatient populations 60,[63][64][65] . They may change on the basis of length of hospital stay 66 and may depend on the age of the patient 65,67 . In addition, more specific attributes of the causative microorganism, for example, the presence of antibiotic-resistant populations 61 or whether an organism was recovered through surveillance culture or from a diagnostic specimen 64 , could be recorded.…”

Section: The Institutional Antibiogrammentioning

confidence: 99%

Developmental roadmap for antimicrobial susceptibility testing systems

et al. 2018

View full text Add to dashboard Cite

Antimicrobial susceptibility testing (AST) technologies help to accelerate the initiation of targeted antimicrobial therapy for patients with infections and could potentially extend the lifespan of current narrow-spectrum antimicrobials. Although conceptually new and rapid AST technologies have been described, including new phenotyping methods, digital imaging and genomic approaches, there is no single major, or broadly accepted, technological breakthrough that leads the field of rapid AST platform development. This might be owing to several barriers that prevent the timely development and implementation of novel and rapid AST platforms in health-care settings. In this Consensus Statement, we explore such barriers, which include the utility of new methods, the complex process of validating new technology against reference methods beyond the proof-of-concept phase, the legal and regulatory landscapes, costs, the uptake of new tools, reagent stability , optimization of target product profiles, difficulties conducting clinical trials and issues relating to quality and quality control, and present possible solutions.

show abstract